Dyslipidemia in patients with chronic kidney disease: etiology and management

Česká verzia

Authors: Magdaléna Dušejovská ^1,2; Marek Vecka ²; Ivan Rychlík ³; Aleš Žák ²
Authors place of work: Dialyzační středisko Fresenius Medical Care Praha 10 – Královské Vinohrady ¹; IV. interní klinika 1. LF UK a VFN Praha ²; I. interní klinika 3. LF UK a FN Královské Vinohrady Praha ³
Published in the journal: Vnitř Lék 2020; 66(5): 275-281
Category:

Summary

The worldwide population is burdened with chronic kidney disease (CKD) from 10–13 %. Patients with CKD subsequently die to cardiovascular disease (CVD) and their complications. In the Czech population, in 2016, the number of patients with end stage renal disease (ESRD) on regular dialytic treatment was 6 739, or 674/1 000 000 inhabitants. Overall mortality in regular dialysis treatment patients was 18.4 % in 2016, of which 43 % died of cardiovascular complications. In view of this fact, a number of expert groups are concerned, among other things, with the problems of lipid metabolism disorders, with the aim of finding a common predictive marker (preferably also therapeutically qualifiable) to stratify patients dialyzed or potentially indicating hypolipidemic therapy. The aim of possible interventions is to minimize cardiovascular risk and subsequent complications resulting from cardiovascular disease (CVD), thus improving the quality of life of regular dialysis treatment patients.

Keywords:

dyslipidemia – chronic kidney disease – hypolipidemic therapy – regular dialysis treatment

Zdroje

1. Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int 2014; 85: 1303–1309.

2. Vostalová J, Galandaková A, Štrebl P, et al. Oxidační stres u pacientů s náhradou funkce ledvin hemodialýzou a peritoneální dialýzou. Vnitř Lék 2012; 58: 466–472.

3. Ellis RJ, Small DM, Ng KL, et al. Indoxyl Sulfate Induces Apoptosis and Hypertrophy in Human Kidney Proximal Tubular Cells. Toxicol Pathol 2018; 46: 449–459.

4. Atamer A, Kocyigit Y, Ecder SA, et al. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. J Nephrol 2008; 21: 924–930.

5. Tribble DL, Rizzo M, Chait A, et al. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low‑density lipoproteins. Am J Med 2001; 110: 103–110.

6. Kwiterovich jr. PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low‑density lipoprotein heterogeneity. Am J Cardiol 2002; 90: 30i–47i.

7. Chait A, Brazg RL, Tribble DL, et al. Susceptibility of small, dense, low‑density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94: 350–356.

8. Kotani K, Tsuzaki K, Traniguchi N, et al. LDL particle size and reactive oxygen metabolities in dyslipidemic patients. Int J Prev Med 2012; 3: 160–166.

9. Gardner CD, Fortmann SP, Krauss RM. Association of small low‑density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875–881.

10. Galeano NF, Al‑Haideri M, Keyserman F, et al. Small dense low density lipoprotein has increased affinity for LDL receptor‑independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 1998; 39: 1263–1273.

11. Milionis HJ, Elisaf MS, Tselepis A, et al. Apolipoprotein(a) phenotypes and lipoprotein( a) concentrations in patients with renal failure. Am J Kidney Dis 1999; 33: 1100–1106.

12. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10: 672–679.

13. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein( a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11: 105–115.

14. Žák A, Zeman M. Sekundární dyslipidémie. In: Svačina Š (ed.) Poruchy metabolismu a výživy. Praha: Galén 2010, 271–288.

15. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211–228.

16. Dodani S, Grice DG, Joshi S. Is HDL function as important as HDL quantity in the coronary artery disease risk assessment? J Clin Lipidol 2009; 3: 70–77.

17. Dantoine TF, Debord J, Charmes JP, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9: 2082–2088.

18. Weichhart T, Kopecky C, Kubicek M, et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934–947.

19. Dušejovská M, Staňková B, Vecka M, et al. Lipid Metabolism in Patients with End‑Stage Renal Disease: A Five‑Year Follow‑up Study. Curr Vasc Pharmacol 2018; 16: 298–305.

20. Movva R, Rader DJ. Laboratory assement of HDL heterogenity and function. Clin Chem 2008; 54: 788–800.

21. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets 2008; 9: 196–203.

22. Tesař V Metabolické aspekty nemoci ledvin. In: Svačina Š (ed.) Poruchy metabolismu a výživy. Praha: Galén 2010, 137–150.

23. de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015; 3: 181–190.

24. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima‑media thickness in low‑risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297: 1344–1353.

25. Su X, Zhang L, Lv J, et al. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta‑analysis. Am J Kidney Dis 2016; 67: 881–892.

26. Kim S, Ko K, Park S, et al. Effect of Fenofibrate Medication on Renal Function. Korean J Fam Med 2017; 38: 192–198.

27. Broeders N, Knoop C, Antoine M, et al. Fibrate‑induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent. Nephrol Dial Transplant 2000; 15: 1993–1999.

28. Paul S, Mohan V. Fenofibrate can increase serum creatinine levels in renal insufficiency. J Assoc Physicians India 2006; 54: 337.

29. McQuade CR, Griego J, Anderson J, et al. Elevated serum creatinine levels associated with fenofibrate therapy. Am J Health Syst Pharm 2008; 65: 138–141.

30. Lipscombe J, Lewis GF, Cattran D, et al. Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001; 55: 39–44.

31. Ritter JL, Nabulsi S. Fenofibrate‑ induced elevation in serum creatinine. Pharmacotherapy 2001; 21: 1145–1149.

32. Ansquer JC, Dalton RN, Caussé E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008; 51: 904–913.

33. Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002; 92: 536–541.

34. Zeman M, Žák A, Vecka M, et al. Treatment of hypertriglyceridemia with fenofibrate, fatty acid composition of plasma and LDL, and their relations to parameters of lipoperoxidation of LDL. Ann N Y Acad Sci 2002; 967: 336–341.

35. Kremer AE, Mettang T. Pruritus in systemic diseases: Common and rare etiologies. Hautarzt 2016; 67: 606–614.

36. Toth PP, Dwyer JP, Cannon CP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 2018; 93: 1397–1408.

37. Bláha V, Bláha M, Lánská M, et al. LDL‑aferéza v léčbě familiárních hyperlipoproteinemií. Vnitř Lék 2014; 60: 970–976.

38. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–2047.

39. Dron JS, Hegele RA. Genetics and lipoprotein Disorders and Traits. Curr. Genet. Med. Rep. 2016; 4: 130–141.